Results 31 to 40 of about 552 (131)

Targeting Olokizumab-Interleukin 6 interaction interface to discover novel IL-6 inhibitors

Journal of Biomolecular Structure and Dynamics, 2023
The IL-6/IL-6R or IL-6/GP130 protein-protein interactions play a significant role in controlling the development of chronic inflammatory diseases, such as rheumatoid arthritis, Castleman disease, psoriasis, and, most recently, COVID-19. Modulating or antagonizing protein-protein interactions of IL6 binding to its receptors by oral drugs promises ...
Que-Huong Tran, Hoang-Nhi Cao, Dac-Nhan Nguyen, Thi-Thuy-Nga Tran, Minh-Tri Le, Quoc-Thai Nguyen, Van-Thanh Tran, Viet-Hung Tran, Khac-Minh Thai   +8 more
openaire   +2 more sources

Experience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes

Научно-практическая ревматология, 2023
The aim of the study was to evaluate in real clinical practice the effectiveness of therapy with an interleukin-6 inhibitor (olokizumab) in patients with rheumatoid arthritis (RA) in terms of clinical and laboratory activity of the disease, as well as ...
N. A. Lapkina, A. A. Baranov, N. E. Abaytova, E. A. Leontyeva, N. V. Yaltseva, A. S. Shutov, E. L. Nasonov   +6 more
doaj   +1 more source

Comparative efficacy of olokizumab and tocilizumab in hospitalized patients with COVID-19

Clinical pharmacology and therapy, 2022
To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.
S. Moiseev, N. Soloveva, L. Akulkina, P. Potapov, E. Tao, N. Bulanov, E.A. Nabatchikova, P. Novikov, M. Brovko   +8 more
openaire   +1 more source

Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic

Научно-практическая ревматология, 2023
The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic anti-inflammatory drugs (DMARDs) and ...
A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev   +11 more
doaj   +1 more source

Clinical cases of complicated diverticulitis against the background of severe course COVID-19. Case report

Терапевтический архив, 2022
Two clinical cases of perforation of a previously undiagnosed colon diverticulum in patients with coronavirus infection caused by the SARS-CoV-2 virus treated at the Hospital №1 of Nalchik.
Natalia Yu. Pshenichcnaya, Zhanna B. Ponezheva, Asiyat R. Marzhokhova, Zaira F. Kharaeva, Liana E. Balagova, Madina Yu. Marzhokhova, Irina V. Shestakova   +6 more
doaj   +1 more source

A clinical case of a sepsis-like course of coronavirus infection on the background of primary metabolic gout

Лечащий Врач, 2023
Background. It is often believed that gout is an uncommon disease and therefore of little interest to general practitioners. However, the incidence of gout in the world is steadily increasing, which is explained by the increase in the population of ...
A. O. Mikhailov, S. A. Sokotun, A. I. Dubikov, N. G. Plekhova, A. I. Simakova, S. A. Petukhova, I. V. Ubozhenko, I. V. Volodina   +7 more
doaj   +1 more source

Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. [PDF]

Ann Rheum Dis
europepmc   +3 more sources

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Современная ревматология, 2023
Objectives To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).Methods In ...
E. Feist, S. Fatenejad, S. Grishin, E. Korneva, M.E. Luggen, E. Nasonov, M. Samsonov, J.S. Smolen, R.M. Fleischmann   +8 more
doaj   +1 more source

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real clinical practice in Kazakhstan

Современная ревматология, 2020
Objective: Olokizumab (OKZ) is one of the innovative biologic treatments for rheumatoid arthritis (RA) targeting interleukin-6 (IL-6). The study purpose was to evaluate the 24-week efficacy and safety of OKZ in routine clinical practice among RA patients
G. A. Togizbayev, D. I. Parpiyeva, D. A. Maksot   +2 more
doaj  

Antibodies to watch in 2021

mAbs, 2021
In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody therapeutics development that occurred in 2020 and forecast events that might occur in 2021.
Hélène Kaplon, Janice M. Reichert
doaj   +1 more source